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Stable Atherosclerotic Disease: A Phase II
Study of Safety, Tolerability, and
Anti-Inﬂammatory ActivityPrevious reports have demonstrated that oxidized
low-density lipoprotein (oxLDL) is a key mediator in
atherogenesis (1). oxLDL increases endothelial cell
adhesion molecules, recruitment of inﬂammatory
cells into the vessel wall, and formation of foam
cells, all hallmarks of atherosclerosis (1). In pre-
clinical models, antibodies to oxLDL decreased
atherosclerotic burden (2). Accordingly, available
data have suggested that oxLDL antibody therapy
may attenuate atherosclerotic inﬂammation and sta-
bilize plaques.
Positron emission tomography (PET) imaging with
18F-ﬂuorodeoxyglucose (FDG) is used to quantify
arterial inﬂammation. PET imaging measures of FDG
uptake are reproducible, correlate with macrophage
inﬁltration, are predictive of future clinical cardio-
vascular events, and are modiﬁable by antiathero-
sclerotic interventions (3). As such, this imaging
approach has been widely adopted for noninvasive
assessment of plaque inﬂammation in response to
interventions.
The GLACIER (Goal of Oxidized LDL and Activated
Macrophage Inhibition by Exposure to a Recombinant
Antibody) trial is the ﬁrst multicenter, randomized,
double-blind study evaluating an anti-oxLDL targeted
monoclonal antibody in patients with stable inﬂam-
matory vascular lesions. We tested the hypothesis
that selective inhibition of oxLDL by MLDL1278A, a
recombinant immunoglobulin G1 antibody targeting
a malondialdehyde-modiﬁed epitope of ApoB-100,
reduces atherosclerotic inﬂammation (as assessed
with FDG-PET). The study population consisted of
147 participants (83% male; mean age 63.0  9.0
years) with atherosclerosis and evidence of carotid or
aortic plaque inﬂammation, measured by FDG-PET/
computed tomography (CT). Patients were random-
ized 1:1:1 to receive MLDL1278A in: 1) a single intra-
venous (IV) infusion, followed by placebo to maintain
blinding; 2) multiple IV infusions; or 3) multiple pla-
cebo IV infusions (Figure 1A). Patients remained on
standard-of-care therapy, including backgroundstatins, and underwent serial FDG-PET/CT scans.
Serum biomarkers were obtained concurrently with
imaging.
Arterial FDG uptake was assessed as target-
to-background ratio (TBR). The artery with the
highest TBR at baseline was identiﬁed as the index
vessel. A focal measure of arterial FDG activity, most
diseased segment (MDS)-TBR, deﬁned as 3 contig-
uous segments centered on the arterial slice demon-
strating the highest FDG uptake at baseline, was
determined. The primary outcome variable was
change in index vessel MDS-TBR measured by FDG-
PET/CT from baseline to week 12. Secondary out-
comes were: 1) change in index vessel MDS-TBR from
baseline to week 4; 2) incidence of adverse events;
and 3) presence of antitherapeutic antibodies to
MLDL1278A.
Baseline demographics were comparable among
groups for the 117 patients with evaluable week 12
FDG-PET images included in the primary analyses.
Although high serum concentrations of MLDL1278A
were achieved throughout the study for both treat-
ment groups, treatment did not signiﬁcantly reduce
arterial inﬂammation (primary endpoint of index
vessel MDS-TBR) versus placebo (Figures 1B and 1C).
MLDL1278A was well tolerated, and there was no
evidence of immunogenicity. Notably, a nominal in-
crease in the levels of tumor necrosis factor alpha
(p ¼ 0.03) and interleukin 6 (p ¼ 0.04) occurred at
4 weeks in the multiple-dose group. No signiﬁcant
decreases in lipid parameters or high-sensitivity
C-reactive protein level were observed in either
group. Further, none of the secondary outcomes were
different between groups.
The hypothesized mechanism of action of
MLDL1278A involves immune complex formation
with oxLDL within plaques, resulting in inhibition
of inﬂammatory macrophages. It is possible that
MLDL1278A binding may be restricted to oxLDL-rich
inﬂamed plaques, which may have been less com-
mon in this population with stable cardiovascular
disease on background statins. Indeed, statin therapy
has been shown to reduce lipoprotein oxidation
biomarker levels. Accordingly, it is plausible that a
larger number of patients may be required to detect
an incremental effect of MLDL1278A on plaque
burden and progression. Further, it is possible that
a follow-up period of 3 months and lack of coronary
artery assessment may be inadequate to assess
potential anti-inﬂammatory effects of MLDL1278A.
FIGURE 1 Schema and Primary Endpoint Analysis of Index Vessel MDS-TBR
(A) Treatment schematic. No signiﬁcant (B) absolute or (C) percent change from baseline
across groups. *Whiskers indicate standard error. FDG ¼ 18F-ﬂuorodeoxyglucose; MDS ¼
most diseased segment; PET ¼ positron emission tomography; TBR ¼ target-to-
background ratio.
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494However, it should be noted that other prospec-
tive FDG-PET/CT studies examining arterial wall
inﬂammation have observed signiﬁcant treatment
effects as early as 1 to 4 months (3), and recent
studies have demonstrated that changes in FDG ac-
tivity in large arteries mirror those in the coronary
circulation.
Although MLDL1278A did not reduce either im-
aging or circulating markers of inﬂammation in
this study, this ﬁnding is not necessarily general-
izable to other antibody-based approaches targeting
oxLDL, which may target other oxLDL epitopes
and have distinct in vitro effects. Future thera-
peutic approaches, such as vaccination againstoxLDL or administration of immunoglobulin M class
anti–oxidized phospholipid, warrant investigation
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